Six independently built ageing clocks agree on the same 42 patients from Insilico's lung trial
The six clocks agreeing matters more than the years they report, because a drug that quiets an inflamed lung moves the same blood proteins whether or not it slows ageing anywhere else.
The Product Desk
What happened
- Insilico Medicine's analysis of its AI-designed drug rentosertib, published in Nature Biotechnology, reworks blood samples from an existing phase 2a lung study rather than reporting a new trial.
- Forty-two of the 71 patients in that phase 2a study consented to proteomic profiling, giving samples at baseline and at weeks two, four and twelve.
- Six clocks built by different groups using different methods scored 2,841 proteins from an Olink panel against a reference population of 55,319 UK Biobank profiles.
- The largest effect came at week four in the 30mg twice-daily arm, where the chronological clocks put treated patients between 2.7 and 3.5 years younger than expected.
- Rentosertib entered phase 3 in July, which is where the efficacy question gets answered for the lung and not for ageing.
Why it matters
- What it limits constraint Since no medicines regulator licenses a drug on a change in proteomic age, the ageing claim cannot travel with the lung programme through approval, and has to make its case in press coverage and investor material instead.
- Who's exposed exposure Insilico's number is now open to correction by strangers rather than only to peer review, because the company deposited the samples and open-sourced the pipelines that produced it.
- What doesn't add up contradiction Insilico's own summary tops out at six years, roughly 1.7 times the highest figure the week-four analysis actually measured, so the company's framing and its paper do not describe the same finding.
- Who has to decide decision Seven liver-toxicity discontinuations, four of them in patients also taking nintedanib, put a dosing choice in front of whoever designs phase 3 arms intended to run on top of the existing standard of care.
Next story · Invest · yesterday
AstraZeneca's insitro deal puts 2.7% of its disclosed value up frontConfirmed4 publishers
Forty-two people with scarred lungs signed a second consent form and gave blood at baseline and at weeks two, four and twelve [3]. That is 59 percent of the trial's patients and the entire dataset behind the years [15].
Those samples were scored on 2,841 proteins against a reference population of 55,319 UK Biobank profiles [4]. Idiopathic pulmonary fibrosis is itself an inflammatory disease that shows up in blood proteins [8], which means a drug that quiets the lung and a drug that slows ageing can produce the same reading. The paper's authors say plainly that they cannot yet tell the two apart [7]. Their mitigation is that the 30mg twice-daily arm reversed age-associated protein patterns while the placebo group drifted along a normal ageing trajectory, which the analysis treats as suggestive rather than settled [9].
Michael Levitt, the 2013 chemistry Nobel laureate, said what convinces him is the agreement rather than the size of the effect, because the six models share neither their features nor their training data [17]. Independent models converging rules out one group's feature selection manufacturing the number by itself. It does not rule out a confound sitting upstream of all six, because all six are reading the same 42 people's blood.
The trial underneath was built to answer a different question. Its primary endpoint was safety, across 21 Chinese sites over 12 weeks, with adverse events at similar rates in every arm [12]. The 60mg once-daily group gained 98.4ml of forced vital capacity while placebo lost 20.3ml [13], a gap of 118.7ml [22]. Nintedanib and pirfenidone, the two approved antifibrotics, slow the decline in lung function rather than halt or reverse it [21], so a measured gain is the result worth having on its own terms. Alex Zhavoronkov, Insilico's founder and co-CEO, gets from the proteomic work to three years added to everyone's life and trillions of dollars in productivity and savings [16], which is a long way downstream of a week-four reading in one dose arm of a 42-person substudy [5].
A surrogate metric earns the right to drive anything if it predicts the outcome you care about in a population like the one you are measuring, and if it cannot also move for a reason your intervention already explains. Proteomic ageing scores clear the first bar: they predict mortality and the risk of common age-related disease across large and diverse populations, with organ-specific versions validated on similar cohorts [10]. They stumble on the second, because in patients whose disease is inflammatory and visible in blood proteins, the metric can move for exactly that reason [8]. A metric that predicts well and moves for reasons you already knew about is the one that makes a report look productive while teaching nobody anything, and the clocks sit in that quadrant here in a way they would not in a cohort with healthy lungs.
For anyone deciding what to do with this, the figure that survives scrutiny is the 118.7ml in a safety-primary study, and the biological age number stays a hypothesis with 42 people in it until a group outside Insilico reproduces it.
What to watch
- An outside group rerunning the deposited samples through its own clocks and landing outside 2.7 to 3.5 years.
- Whether phase 3 collects proteomic samples at all, and whether any regulator is asked to look at them.
- Whether phase 3 reports a measured gain in forced vital capacity rather than a slower loss.
Clarity's read
What the record supports and how the coverage leans. The claims behind it follow.
Reality
- Evidence42
- Adoption5
- Hype gap+45
- Incentives70
- Confidence62
Perspective Coverage
3 publishers- Builder
- Builder 45%
- Operator
- Operator 32%
- Investor
- Investor 23%
Claim ledger
Ranked by verification strength, evidence, and original report placement.
- [1]
Insilico Medicine published in Nature Biotechnology a secondary analysis of rentosertib, rather than a new trial.
- [2]
Rentosertib is a TNIK inhibitor for idiopathic pulmonary fibrosis that Insilico Medicine designed using generative AI.
- [3]
Of the 71 patients in rentosertib's phase 2a study, 42 consented to proteomic profiling, giving samples at baseline and at weeks two, four and twelve.
- [4]
Some 2,841 proteins were measured on an Olink panel and scored against six clocks built by different groups using different methods, with 55,319 UK Biobank profiles as the reference population.
- [5]
The largest effect appeared at week four in the 30mg twice-daily arm, where the chronological clocks put the treated patients between 2.7 and 3.5 years younger than expected.
- [6]
All six ageing clocks returned the same answer: the patients on the drug looked biologically younger than the patients on placebo.
- [7]
The authors write that the study cannot yet separate slower ageing from a treated lung.
- [8]
Idiopathic pulmonary fibrosis is itself an inflammatory disease that shows up in blood proteins, so a drug that improves the lung would be expected to move the same markers without touching ageing anywhere else.
- [9]
The authors attempted to address the confound by showing that the 30mg twice-daily arm reversed age-associated protein patterns while placebo drifted along a normal ageing trajectory, which is suggestive rather than conclusive.
- [10]
Proteomic ageing scores of this kind predict mortality and the risk of common age-related disease across large and diverse populations, and organ-specific versions have been validated on similar cohorts.
- [11]
No medicines regulator licenses a drug on a change in proteomic age.
- [12]
The trial's primary endpoint was safety; across 21 Chinese sites over 12 weeks, adverse events occurred at similar rates in every arm.
- [13]
The 60mg once-daily group gained 98.4ml of forced vital capacity against a 20.3ml decline on placebo.
- [14]
Insilico's own summary of the work describes roughly three to four years, and up to six on certain clocks, which is the upper end of the range rather than its centre.
- [15]
The 42 consenting patients are 59 percent of the 71 patients in the phase 2a study.
- [16]
Alex Zhavoronkov, founder and co-CEO of Insilico Medicine, said: "If you manage to add 3 years to everyone's life, the drug should be able to significantly extend the healthy portion of life as well, translating into trillions of dollars in productivity and savings."
- [17]
Michael Levitt, the 2013 chemistry Nobel laureate, said: "Six proteomic clocks from six independent groups, applied to the same 42 patients, all reported a younger biological age in the treated arms. What convinces me is not the size of the effect but the agreement, because these models share neither their features nor their training data."
- [18]
Seven patients discontinued because of liver toxicity, four of them while also taking nintedanib, the existing standard of care.
- [19]
Rentosertib entered phase 3 in July, which is where the efficacy question gets answered for the lung, though not for ageing.
- [20]
Insilico deposited the proteomic data with the China National Center for Bioinformation and released its analysis pipelines as open-source software, which makes the claim checkable by people who did not write it.
- [21]
The two approved antifibrotics, nintedanib and pirfenidone, slow the decline in lung function rather than halt or reverse it.
- [22]
The gap between the 60mg once-daily arm and placebo on forced vital capacity is 118.7ml.
- [23]
The six-year upper figure in Insilico's summary is about 1.7 times the top of the measured week-four range of 3.5 years.
Sources
3 independent publishers whose own reporting we read for this story.
- digitaltrends.comAn AI-designed drug might help slow aging, but we’re not there yet - Digital Trends
1 article · September 8, 2026
- gizmodo.comStudy Suggests AI-Generated Drug Could Slow Aging
1 article · September 7, 2026
- thenextweb.comInsilico says its AI-designed lung drug lowered biological age markers in a 42-patient trial
1 article · September 7, 2026
Topics and entities
Topics
- AI Drug Discovery
- Proteomics
- Idiopathic Pulmonary Fibrosis
- Biological ageing clocks
Entities
- Alex Zhavoronkov
- China National Center for Bioinformation
- Nature Biotechnology
- Insilico Medicine
- UK Biobank